Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast : a randomised controlled trial investigating the <font color="blue">effects_2</font> <font color="blue">on_1</font> <font color="blue">airway_2</font> <font color="blue">inflammation_2</font> in asthma . 
<br>
<br> BACKGROUND Few studies have compared <font color="blue">treatment_1</font> <font color="blue">strategies_1</font> <font color="blue">in_1</font> <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">asthma_1</font> poorly controlled on low dose inhaled corticosteroids , and little is known about the <font color="blue">effects_1</font> <font color="blue">of_1</font> <font color="blue">different_1</font> <font color="blue">treatments_1</font> <font color="blue">on_1</font> <font color="blue">airway_2</font> <font color="blue">inflammation_2</font> <font color="blue">._2</font> In this double - blind , placebo - controlled , parallel group study , we compared the <font color="blue">effects_1</font> <font color="blue">of_1</font> <font color="blue">salmeterol_1</font> <font color="blue">plus_1</font> <font color="blue">fluticasone_1</font> <font color="blue">propionate_1</font> <font color="blue">(_1</font> <font color="blue">FP_1</font> <font color="blue">)_1</font> <font color="blue">(_1</font> <font color="blue">Seretide_1</font> <font color="blue">;_1</font> <font color="blue">SFC_1</font> <font color="blue">)_1</font> <font color="blue">and_1</font> <font color="blue">FP_1</font> <font color="blue">plus_1</font> <font color="blue">montelukast_1</font> <font color="blue">(_1</font> <font color="blue">FP_1</font> <font color="blue">/_1</font> <font color="blue">M_1</font> <font color="blue">)_1</font> <font color="blue">on_1</font> <font color="blue">sputum_3</font> <font color="blue">inflammatory_3</font> <font color="blue">markers_3</font> <font color="blue">,_3</font> <font color="blue">airway_3</font> <font color="blue">responsiveness_3</font> <font color="blue">,_3</font> <font color="blue">lung_3</font> <font color="blue">function_3</font> <font color="blue">,_3</font> <font color="blue">and_3</font> <font color="blue">symptoms_3</font> <font color="blue">in_2</font> <font color="blue">adult_2</font> <font color="blue">asthmatics_2</font> <font color="blue">._2</font> 
<br> METHODS Sixty - six subjects were randomised to SFC or FP / M for 12 weeks . The primary outcome was <font color="blue">changes_3</font> <font color="blue">in_3</font> <font color="blue">neutrophil_4</font> <font color="blue">,_4</font> <font color="blue">eosinophil_4</font> <font color="blue">,_4</font> <font color="blue">macrophage_4</font> <font color="blue">,_4</font> <font color="blue">lymphocyte_4</font> <font color="blue">,_4</font> <font color="blue">and_4</font> <font color="blue">epithelial_4</font> <font color="blue">cell_4</font> <font color="blue">levels_4</font> <font color="blue">in_2</font> <font color="blue">induced_2</font> <font color="blue">sputum_2</font> <font color="blue">._2</font> Additional outcomes included the <font color="blue">change_2</font> <font color="blue">in_2</font> <font color="blue">other_2</font> <font color="blue">sputum_4</font> <font color="blue">markers_4</font> <font color="blue">of_4</font> <font color="blue">airway_4</font> <font color="blue">inflammation_4</font> <font color="blue">,_4</font> <font color="blue">airway_4</font> <font color="blue">responsiveness_4</font> <font color="blue">,_4</font> <font color="blue">symptom_4</font> <font color="blue">control_4</font> <font color="blue">,_4</font> <font color="blue">and_4</font> <font color="blue">lung_4</font> <font color="blue">function_4</font> <font color="blue">._4</font> 
<br> RESULTS Both treatments had no significant effect on induced <font color="blue">sputum_1</font> <font color="blue">inflammatory_1</font> cells , although there was a trend for a <font color="blue">reduction_1</font> <font color="blue">in_1</font> <font color="blue">sputum_4</font> <font color="blue">eosinophils_4</font> <font color="blue">._4</font> Both treatments significantly improved <font color="blue">airway_4</font> <font color="blue">responsiveness_4</font> <font color="blue">,_4</font> whereas SFC generally led to <font color="blue">greater_2</font> <font color="blue">improvements_2</font> <font color="blue">in_2</font> <font color="blue">symptom_5</font> <font color="blue">control_5</font> <font color="blue">and_5</font> <font color="blue">lung_5</font> <font color="blue">function_5</font> than FP / M. FP / M led to significantly greater <font color="blue">reductions_1</font> <font color="blue">in_1</font> <font color="blue">sputum_4</font> <font color="blue">cysteinyl_4</font> <font color="blue">leukotrienes_4</font> <font color="blue">than_1</font> <font color="blue">SFC_1</font> ( treatment ratio 1.80 ; 95% CI 1.09 , 2.94 ) . 
<br> CONCLUSION Both treatments led to similar <font color="blue">control_1</font> <font color="blue">of_1</font> <font color="blue">eosinophilic_3</font> <font color="blue">airway_3</font> <font color="blue">inflammation_3</font> <font color="blue">,_3</font> although <font color="blue">PEF_1</font> <font color="blue">and_1</font> <font color="blue">symptom_1</font> <font color="blue">control_1</font> were better with SFC . STUDY NUMBER : SAM40030 ( SOLTA ) .